Abstract：OBJECTIVE To prepare a reduction-responsive nanoparticle (HID-NPs) for indomethacin (IND) and doxorubicin (DOX) delivering and investigate their effects on reversing multidrug resistance in breast cancer. METHODS Hyaluronic acid-based amphiphilic substances (HA-SS-PA) were prepared by amidation reaction, and their structures were confirmed by NMR. HID-NPs were prepared by nano-precipitation method. The particle size measurement and morphology observation of the HID-NPs were measured by dynamic light scanning (DLS) and transmission electron microscopy (TEM), respectively. The reduction-responsive drug release behavior of HID-NPs was determined by dialysis method. Cell uptake HID-NPs on human breast cancer MCF-7/ADR cells were observed by laser confocal microscopy. The cytotoxicity of HID-NPs on human breast cancer MCF-7 and MCF-7/ADR cells was determined by MTT assay. RESULTS1H-NMR spectrum indicated that HA-SS-PA was successfully prepared. The results of DLS and TEM showed that HID-NPs were round and evenly distributed with an average particle size of (103±3.2) nm. Drug release assay indicates that HID-NPs have good reduction-responsiveness ability. Cell uptake experiments demonstrated that HID-NPs significantly increased DOX accumulation in MCF-7/ADR cells compared with free DOX; MTT assays showed that HID-NPs could significantly destroy MCF-7/ADR cells. CONCLUSION HID-NPs shows good reduction-responsiveness and obvious reverse DOX resistance, which can be used for the treatment of multidrug resistance of breast tumors.
闫振宇, 王新伟, 买春阳, 苏博, 张子杰, 韩柯. 还原响应型纳米载体共递送多柔比星和吲哚美辛逆转乳腺癌多药耐药[J]. 中国药学杂志, 2020, 55(11): 925-932.
YAN Zhen-yu, WANG Xin-wei, MAI Chun-yang, SU Bo, ZHANG Zi-jie, HAN Ke. Reduction-Responsive Nanocarrier Co-delivery Indomethacin and Doxorubicin for Overcoming Multi-drug Resistant Breast Cancer. Chinese Pharmaceutical Journal, 2020, 55(11): 925-932.
MICHAEL K K, GALLUS J, VAHDATI S, et al. New inhibitors of breast cancer resistance protein (ABCG2) containing a 2,4-disubstituted pyridopyrimidine scaffold[J]. J Med Chem, 2018, 61(8):3389-3408.
[2]
HUANG Y, HE L, SONG Z, et al. Phycocyanin-based nanocarrier as a new nanoplatform for efficient overcoming of cancer drug resistance[J]. J Mater Chem B, 2017, 5(18):3300-3314.
[3]
ZHAO P, LI L, ZHOU S, et al. TPGS functionalized mesoporous silica nanoparticles for anticancer drug delivery to overcome multidrug resistance[J]. Mater Sci Eng C, 2018, 84:108-117.
[4]
WANG F, LI L, LIU B, et al. Hyaluronic acid decorated pluronic P85 solid lipid nanoparticles as a potential carrier to overcome multidrug resistance in cervical and breast cancer[J]. Biomed Pharmacother, 2017, 86(complete):595-604.
[5]
ZHOU L, WANG H, LI Y. Stimuli-Responsive Nanomedicines for Overcoming Cancer Multidrug Resistance[J]. Theranostics, 2018, 8(4):1059-1074.
[6]
YU J, CHEN H, JIANG L, et al. Codelivery of adriamycin and P-gp inhibitor quercetin using PEGylated liposomes to overcome cancer drug resistance[J]. J Pharm Sci, 2019, 108(5): 1788-1799.
[7]
ZHANG J, WANG L, CHAN H F, et al. Co-delivery of paclitaxel and tetrandrine via iRGD peptide conjugated lipid-polymer hybrid nanoparticles overcome multidrug resistance in cancer cells[J]. Sci Rep, 2017, 7:46057.
[8]
JOHNSON Z L, CHEN J. ATP binding enables substrate release from multidrug resistance protein 1[J]. Cell, 2018, 172(1-2):81-89.
[9]
LEE J Y, TERMSARASAB U, LEE M Y, et al. Chemosensitizing indomethacin-conjugated chitosan oligosaccharide nanoparticles for tumor-targeted drug delivery[J]. Acta Biomater, 2017,57:262-273.
[10]
GROOT D J A D. Indomethacin induces apoptosis via a MRP1-dependent mechanism in doxorubicin-resistant small-cell lung cancer cells overexpressing MRP1[J]. Br J Cancer, 2007, 97(8):1077-1083.
[11]
ZHOU Y, WANG S, YING X, et al. Doxorubicin-loaded redox-responsive micelles based on dextran and indomethacin for resistant breast cancer[J]. Int J Nanomed, 2017, 12:6153-6168.
[12]
HUANG N, CHENG Y. Indomethacin enhances the cytotoxicity of doxorubicin to glioma U251 [J]. Chin J Cell Biol(中国细胞生物学学报), 2013, 35(5): 649-654.
[13]
KOMIN A, RUSSELL L M, HRISTOVA K A, et al. Peptide-based strategies for enhanced cell uptake, transcellular transport, and circulation: mechanisms and challenges[J]. Adv Drug Deliv Rev, 2017,110-111:52-64.
[14]
ZHOU Q, HOU Y, LI Z, et al. Dual-pH sensitive charge-reversal nanocomplex for tumor-targeted drug delivery with enhanced anticancer activity[J]. Theranostics, 2017, 7(7):1806-1819.
[15]
SHU Y, SONG R, ZHENG A, et al. Thermo/pH dual-stimuli-responsive drug delivery for chemo-/photothermal therapy monitored by cell imaging[J]. Talanta, 2018, 181:278-285.
[16]
CHENG Q, TENG K X, DING Y F, et al. Dual stimuli-responsive bispillar
[5]
arene-based nanoparticles for precisely selective drug delivery in cancer cells[J]. Chem Commun, 2019, 55(16):2340-2343.
[17]
ZHAO H, YUAN X, YU J, et al. Magnesium-stabilized multifunctional DNA nanoparticles for tumor-targeted and pH-responsive drug delivery[J]. ACS Appl Mater Interfaces, 2018, 10(18):15418-15427.
[18]
DENG Y, LING J, LI M H. Physical stimuli-responsive liposomes and polymersomes as drug delivery vehicles based on phase transitions in the membrane[J]. Nanoscale, 2018, 10(15):6781-6800.
[19]
UTHAMAN S, MATHEW A P, PARK H J, et al. IR 780-loaded hyaluronic acid micelles for enhanced tumor-targeted photothermal therapy[J]. Carbohydr Polym, 2018, 181:1-9.
[20]
ZHAI S, HU X, HU Y, et al. Visible light-induced crosslinking and physiological stabilization of diselenide-rich nanoparticles for redox-responsive drug release and combination chemotherapy[J]. Biomaterials, 2017, 121:41-54.
[21]
CARVALHO A M, TEIXEIRA R, NOVOACARBALLAL R, et al. Redox-responsive micellar nanoparticles from glycosaminoglycans for CD44 targeted drug delivery[J]. Biomacromolecules, 2018, 19(7):2991-2999.
[22]
KIROVA Y M, CARROLL S, FOURQUET A, et al. The St. Gallen international expert consensus on the primary therapy of early breast cancer 2017: the point of view of an international panel of experts in radiation oncology[J]. Annals Oncol, 2018, 29(1):280-281.
[23]
KINOSHITA R, ISHIMA Y, VTG C, et al. Improved anticancer effects of albumin-bound paclitaxel nanoparticle via augmentation of EPR effect and albumin-protein interactions using S-nitrosated human serum albumin dimer[J]. Biomaterials, 2017, 140:162-169.
[24]
MAEDA H. Polymer therapeutics and the EPR effect[J]. J Drug Target, 2017, 25(9):1-5.
[25]
YU M, JAMBHRUNKAR S, THORN P, et al. Hyaluronic acid modified mesoporous silica nanoparticles for targeted drug delivery to CD44-overexpressing cancer cells[J]. Nanoscale, 2013, 5(1):178-183.
2020, Vol. 55 
